share_log

LevelJump Healthcare Corp. Announces Record Revenues; Q2 Revenue Increase of 34%

LevelJump Healthcare Corp. Announces Record Revenues; Q2 Revenue Increase of 34%

LevelJump Healthcare Corp. 宣布创纪录的收入;第二季度收入增长
newsfile ·  2023/08/29 17:00

Toronto, Ontario--(Newsfile Corp. - August 29, 2023) - LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("LevelJump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce today it has reported financial results for the fiscal quarter ended June 30, 2023. All amounts are expressed in Canadian dollars.

安大略省多伦多-(Newsfile Corp.-2023年8月29日)-加拿大B2B远程医疗解决方案领先企业LevelJump Healthcare Corp.(TSXV:JUMP)(OTCQB:JMPHF)(FSE:75J)(“LevelJump”或“公司”)今天高兴地宣布,公司已公布截至2023年6月30日的财季财务业绩。所有金额均以加元表示。

Financial and Operational Highlights

财务和运营亮点

  • Revenues from Canadian Teleradiology Services, Inc. ("CTS") operations hits record level with $3,122,046 in revenues for the second quarter.

  • Gross profit from CTS operations was $912,353 for the quarter, a 29% margin (2% increase from margins in Q1 2023).

  • CTS Year over Year Q2 revenue increased 34%.

  • 加拿大Teleradiology Services,Inc.(“CTS”)业务第二季度的收入达到创纪录的3122,046美元。

  • 该季度来自CTS业务的毛利润为912,353美元,利润率为29%(比2023年第一季度利润率增长2%)。

  • CTS第二季度收入同比增长34%。

Management Comments

管理意见

"We had another record quarter of revenue and are now tracking over $12 million annually in revenues," said Mitch Geisler CEO. "As our Yonge Sheppard location comes online, and once we close the Alberta acquisition, we expect revenues to grow to over $20 million annually with a margin of over 30%, and the Company's EBITDA to be healthy and consistently positive."

该公司首席执行官米奇·盖斯勒表示:“我们的季度营收再创新高,现在的年营收超过1200万美元。”随着我们的Yonge Seppard分店上线,一旦我们完成对艾伯塔省的收购,我们预计年收入将增长到2000万美元以上,利润率超过30%,公司的EBITDA将保持健康和持续积极的状态。“

Non-IFRS Financial Measures

非国际财务报告准则财务衡量标准

This news release contains financial terms (such as adjusted EBITDA) that are not considered in IFRS. Such financial measures, together with measures prepared in accordance with IFRS, provide useful information to investors and shareholders, as management uses them to evaluate the operating performance of the Company. The Company's determination of these non-IFRS measures may differ from other reporting issuers, and therefore are unlikely to be comparable to similar measures presented by other companies. Further, these non-IFRS measures should not be considered in isolation or as a substitute for measures of performance or cash flows prepared in accordance with IFRS. These financial measures are included because management uses this information to analyze operating performance and liquidity.

本新闻稿包含IFRS中未考虑的财务术语(如调整后的EBITDA)。该等财务措施,连同根据国际财务报告准则编制的措施,为投资者和股东提供有用的信息,因为管理层利用这些措施来评估公司的经营业绩。该公司对这些非国际财务报告准则衡量标准的确定可能与其他报告发行人不同,因此不太可能与其他公司提出的类似衡量标准相比较。此外,不应孤立地考虑这些非《国际财务报告准则》的衡量标准,也不应将其作为根据《国际财务报告准则》编制的业绩衡量标准或现金流的替代指标。这些财务指标之所以包括在内,是因为管理层使用这些信息来分析经营业绩和流动性。

Adjusted EBITDA & Annual Revenue Run Rate

调整后的EBITDA和年度收入运行率

Management believes adjusted EBITDA is a useful supplemental measure to determine the Company's ability to generate cash available for working capital, capital expenditures, debt repayments, interest expense and income taxes.

管理层认为,调整后的EBITDA是确定公司产生可用于营运资本、资本支出、债务偿还、利息支出和所得税的现金能力的有用补充指标。

EBITDA refers to net income (loss) determined in accordance with IFRS, before depreciation and amortization, net interest expense (income) and income tax expense (recovery). The Company defines adjusted EBITDA as EBITDA, plus stock-based compensation expense, restructuring, fair value adjustments, listing expense and transaction costs, impairment and finance income.

EBITDA指按照国际财务报告准则确定的未计折旧和摊销前的净收益(亏损)、净利息支出(收入)和所得税支出(回收)。本公司将调整后的EBITDA定义为EBITDA,加上基于股票的薪酬支出、重组、公允价值调整、上市费用和交易成本、减值和财务收入。

A reconciliation of adjusted EBITDA to net income (loss) is as follows:

调整后的EBITDA与净收益(亏损)的对账如下:

Three Months ended
June 30
Six Months ended
June 30
($ in thousands) 2023 2022 2023 2022
Net and comprehensive income (loss) (237 ) (184 ) (445 ) (527 )
Add back:
Depreciation and amortization 120 53 212 94
Net interest expense 61 36 117 60
Stock-based compensation - 37 - 220
Taxes - - 9 -
Misc and foreign exchange (114 ) 1 (116 ) (86 )
EBITDA (170 ) (57 ) (223 ) (239 )
Add back:
Broker commissions for financing 67 20 67 20
One-time Professional Fees related to Acquisitions 20 175 100 250
Adjusted EBITDA (83 ) 138 (56 ) 31
截至三个月
6月30日
截至六个月
6月30日
(千美元) 2023年 2022 2023年 2022
净收益和综合收益(亏损) (237 ) (184) ) (445) ) (527) )
添加回:
折旧及摊销 120 53 212 94
净利息支出 61 36 117 60
基于股票的薪酬 - 37 - 220
税费 - - 9. -
MISC与外汇 (114) ) 1 (116) ) (86 )
EBITDA (170 ) (57) ) (223 ) (239 )
添加回:
融资的经纪佣金 67 20个 67 20个
与收购相关的一次性专业费用 20个 一百七十五 100个 250个
调整后的EBITDA (83) ) 一百三十八 (56) ) 31

About LevelJump Healthcare
LevelJump Healthcare Corp., (TSXV: JUMP) provides telehealth solutions to client hospitals and imaging centers through its Teleradiology division, as well as in person radiology services through its IHF's (Independent Healthcare Facilities). JUMP focuses primarily on critical care for urgent and emergency patients, establishing integral relationships in the communities we serve.

关于LevelJump Healthcare
LevelJump Healthcare Corp.(多伦多证券交易所股票代码:JUMP)通过其远程放射部门为客户医院和成像中心提供远程医疗解决方案,并通过其IHF(独立医疗设施)提供面对面的放射服务。JUMP主要专注于紧急和紧急患者的危重护理,在我们所服务的社区中建立完整的关系。

ON BEHALF OF THE BOARD OF DIRECTORS OF
LEVELJUMP HEALTHCARE CORP.

我谨代表华为的董事会
LEVELJUMP医疗保健公司。

Mitchell Geisler
Chief Executive Officer

米切尔·盖斯勒
首席执行官

Caitlin-Robyn Densmore
Investor Relations Manager
Caitlin.Densmore@leveljumphealthcare.com
(437) 214-1568

凯特琳-罗宾·丹斯莫尔
投资者关系经理
邮箱:Caitlin.Densmore@Levjumphelthare.com
(437)214-1568

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business plans and the outlook of the Company's industry. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable).

关于前瞻性信息的警示声明
本新闻稿包含与公司业务计划和公司行业前景相关的适用证券法所指的“前瞻性信息”。尽管本公司认为,根据其高级管理人员和董事的经验、当前状况和预期未来发展以及其他被认为合适的因素,这些前瞻性信息中反映的预期是合理的,但不应过度依赖这些预期,因为本公司不能保证这些预期将被证明是正确的。实际结果和发展可能与这些陈述中预期的大不相同。本新闻稿中的陈述是截至本新闻稿发布之日作出的,公司不承担任何责任对其进行更新或修改,以反映除适用证券法所要求的以外的新事件或新情况。本公司没有义务对第三方对本公司、加拿大TelerRadiology Services,Inc.、其证券或其各自的财务或经营业绩(如适用)所作的分析、预期或陈述发表评论。

Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

交易所及其监管服务提供商(该术语在交易所的政策中定义)均不对本新闻稿的充分性或准确性承担责任。

The securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor in any other jurisdiction.

所发行的证券尚未、也不会根据修订后的《1933年美国证券法》(下称《美国证券法》)或美国任何州证券法进行注册,在未进行注册或未获得美国证券法和适用的美国州证券法的注册要求豁免的情况下,不得在美国境内或向美国人、为美国个人或为美国人的利益进行发行或销售。本新闻稿不构成在美国或其他任何司法管辖区出售证券的要约或购买证券的要约。

To view the source version of this press release, please visit

要查看本新闻稿的源版本,请访问

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发